title: Melatonin and mitochondrial dysfunction in the central nervous system.
abstract: Cell death and survival are critical events for neurodegeneration, mitochondria being increasingly seen as important determinants of both. Mitochondrial dysfunction is considered a major causative factor in Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD). Increased free radical generation, enhanced mitochondrial inducible nitric oxide (NO) synthase activity and NO production, and disrupted electron transport system and mitochondrial permeability transition, have all been involved in impaired mitochondrial function. Melatonin, the major secretory product of the pineal gland, is an antioxidant and an effective protector of mitochondrial bioenergetic function. Both in vitro and in vivo, melatonin was effective to prevent oxidative stress/nitrosative stress-induced mitochondrial dysfunction seen in experimental models of AD, PD and HD. These effects are seen at doses 2-3 orders of magnitude higher than those required to affect sleep and circadian rhythms, both conspicuous targets of melatonin action. Melatonin is selectively taken up by mitochondria, a function not shared by other antioxidants. A limited number of clinical studies indicate that melatonin can improve sleep and circadian rhythm disruption in PD and AD patients. More recently, attention has been focused on the development of potent melatonin analogs with prolonged effects which were employed in clinical trials in sleep-disturbed or depressed patients in doses considerably higher than those employed for melatonin. In view that the relative potencies of the analogs are higher than that of the natural compound, clinical trials employing melatonin in the range of 50-100mg/day are needed to assess its therapeutic validity in neurodegenerative disorders.
authors.affiliation: Pontificia Universidad Católica Argentina, Facultad de Ciencias Médicas, 1107 Buenos Aires, Argentina. danielcardinali@uca.edu.ar
authors.forename: Daniel P
authors.initials: DP
authors.lastname: Cardinali
authors.forename: Eleonora S
authors.initials: ES
authors.lastname: Pagano
authors.forename: Pablo A
authors.initials: PA
authors.lastname: Scacchi Bernasconi
authors.forename: Roxana
authors.initials: R
authors.lastname: Reynoso
authors.forename: Pablo
authors.initials: P
authors.lastname: Scacchi
mesh_terms: D000544:Alzheimer Disease / Q000378:metabolism*; D000818:Animals; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism*; D008550:Melatonin / Q000378:metabolism* / Q000494:pharmacology / Q000627:therapeutic use; D008928:Mitochondria / Q000378:metabolism / Q000502:physiology*; D010300:Parkinson Disease / Q000378:metabolism*
chemical_list: D008550:Melatonin